Ian Mortimer Biography and Net Worth

President and Chief Executive Officer of Xenon Pharmaceuticals

Ian Mortimer has served as our President and Chief Executive Officer since June 2021, previously serving as President and Chief Financial Officer since March 2018. Mr. Mortimer previously served as our Corporate Secretary from June 2015 to March 2021, as our Chief Financial Officer and Chief Operating Officer since March 2015 and as our Chief Financial Officer since October 2013. Prior to joining us, Mr. Mortimer served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma Corporation), a Nasdaq-listed biotechnology company, from 2007 until October 2013. Mr. Mortimer was responsible for all aspects of Tekmira’s finance and capital markets activities and led Tekmira’s listing on Nasdaq in 2010. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals and held various other positions at Inex Pharmaceuticals from 1997 to 2004. Since July 2020, Mr. Mortimer has served on the board of directors of Perimeter Medical Imaging AI, Inc., a publicly-traded medical device company focused on advanced in procedural medical imaging tools. Mr. Mortimer has an M.B.A. from Queen’s University, a B.Sc. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant.

What is Ian Mortimer's net worth?: The estimated net worth of Ian Mortimer is at least $927,600.03 as of May 24th, 2023. Mr. Mortimer owns 24,213 shares of Xenon Pharmaceuticals stock worth more than $927,600 as of November 18th. This net worth estimate does not reflect any other investments that Mr. Mortimer may own. Additionally, Mr. Mortimer receives a salary of $1,070,000.00 as President and Chief Executive Officer at Xenon Pharmaceuticals. Learn More about Ian Mortimer's net worth.
How old is Ian Mortimer?: Mr. Mortimer is currently 48 years old. There are 7 older executives and no younger executives at Xenon Pharmaceuticals. Learn More on Ian Mortimer's age.
What is Ian Mortimer's salary?: As the President and Chief Executive Officer of Xenon Pharmaceuticals Inc., Mr. Mortimer earns $1,070,000.00 per year. Learn More on Ian Mortimer's salary.
How do I contact Ian Mortimer?: The corporate mailing address for Mr. Mortimer and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Ian Mortimer's contact information.
Has Ian Mortimer been buying or selling shares of Xenon Pharmaceuticals?: Ian Mortimer has not been actively trading shares of Xenon Pharmaceuticals within the last three months. Most recently, Ian Mortimer sold 31,655 shares of the business's stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $41.41, for a transaction totalling $1,310,833.55. Following the completion of the sale, the chief executive officer now directly owns 24,213 shares of the company's stock, valued at $1,002,660.33. Learn More on Ian Mortimer's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 31,517 shares worth more than $1,379,060.56. The most recent insider tranaction occured on March, 7th when EVP Sherrington Robin sold 7,137 shares worth more than $330,300.36. Insiders at Xenon Pharmaceuticals own 5.5% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 3/7/2024.

Ian Mortimer Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/24/2023	Sell	31,655	$41.41	$1,310,833.55	24,213
8/10/2017	Buy	15,000	$2.88	$43,200.00	6,000
6/24/2016	Buy	5,300	$6.22	$32,966.00	1,000

Ian Mortimer Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $38.31

$37.38

$40.04

50 Day Range

MA: $41.21

$38.06

$45.74

2 Week Range

Now: $38.31

$28.20

$50.99

Volume

878,189 shs

Average Volume

389,378 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

DeFi Coin on Verge of Breakout!

From Crypto 101 Media | Ad

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!

Ian Mortimer Biography and Net Worth

What is Ian Mortimer's net worth?

How old is Ian Mortimer?

What is Ian Mortimer's salary?

How do I contact Ian Mortimer?

Has Ian Mortimer been buying or selling shares of Xenon Pharmaceuticals?

Who are Xenon Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Xenon Pharmaceuticals?